The DOI matches its Crossref record; 26 of the 28 references it cites were found in a registry or an index.
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
Abstract
The mode of action of Ecteinascidin-743 (ET-743), a marine tetrahydroisoquinoline alkaloid isolated from Ecteinascidia turbinata, which has shown very potent antitumour activity in preclinical systems and encouraging results in Phase I clinical trials was investigated at a cellular level. Both SW620 and LoVo human intestinal carcinoma cell lines exposed for 1 h to ET-743 progress through S phase more slowly than control cells and then accumulate in the G2M phase. The sensitivity to ET-743 of G1 synchronised cells was much higher than that of cells synchronised in S phase and even higher than that of cells synchronised in G2M. ET-743 concentrations up to four times higher than the IC(50) value caused no detectable DNA breaks or DNA-protein cross-links as assessed by alkaline elution techniques. ET-743 induced a significant increase in p53 levels in cell lines expressing wild-type (wt) (p53). However, the p53 status does not appear to be related to the ET-743 cytotoxic activity as demonstrated by comparing the drug sensitivity in p53 (-/-) or (+/+) mouse embryo fibroblasts and in A2780 ovarian cancer cells or the A2780/CX3 sub-line transfected with a dominant-negative mutant TP53. The cytotoxic potency of ET-743 was comparatively evaluated in CHO cell lines proficient or deficient in nucleotide excision repair (NER), and it was found that ET-743 was approximately 7-8 times less active in ERCC3/XPB and ERCC1-deficient cells than control cells. The findings that G1 phase cells are hypersensitive and that NER-deficient cells are resistant to ET-743 indicate that the mode of action of ET-743 is unique and different from that of other DNA-interacting drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, ET-743, a tetrahydroisoquinilone alkaloid isolated from tunicate Ecteinascidia turbinata entered phase I clinical trials [62], since it exerts anti-proliferative effects by selective alkylation of guanine residues in the DNA minor groove [63], whereas dolastatin 10, a member of a peptide family isolated from the mollusk Dolabella auricularia, reached phase II clinical trials [64], based”
From Marine Natural Products: A Source of Novel Anticancer Drugs (2019) · cites this paper as [63]
Citations
Cites
RINEHART, K. L. J., Holt, T. G., Fregeau, N. L., Stroh, J. G., Keifer, P. A., Sun, F.-R., Li, L. H., & Martin, D. G. (1990) · The Journal of Organic Chemistry · doi:10.1021/jo00302a007 · Cited by 493
Pommier, Y. G., Kohlhagen, G., Bailly, C., Waring, M. J., Mazumder, A., & Kohn, K. W. (1996) · Biochemistry · doi:10.1021/bi960306b · Cited by 304
Drummond, J. T., Anthoney, A., Brown, R. E., & Modrich, P. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.19645 · Cited by 295
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.
Fink, D. A., Zheng, H., Nebel, S., Norris, P. S., Aebi, S. P., Lin, T., Nehmé, A., Christen, R. D., Haas, M., MacLeod, C. L., et al. (1997) · PubMed · Cited by 277
Ecteinascidin 743: A Minor Groove Alkylator That Bends DNA toward the Major Groove
Zewail‐Foote, M., & Hurley, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990241l · Cited by 219
Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
Jin, S. V., Gorfajn, B., Faircloth, G. T., & Scotto, K. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6775 · Cited by 206
Self-citationInterference of transcriptional activation by the antineoplastic drug ecteinascidin-743
Minuzzo, M., Marchini, S., Broggini, M., Faircloth, G. T., D’Incalci, M., & Mantovani, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6780 · Cited by 195
Self-citationMartinez, E. J., Owa, T., Schreiber, S. L., & Corey, E. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3496 · Cited by 170
Rice, J. A., Crothers, D. M., Pinto, A. L., & Lippard, S. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.12.4158 · Cited by 168
Izbicka, E., Lawrence, R., Raymond, É., Eckhardt, G., Faircloth, G. T., Jimeno, J. M., Clark, G. M., & VonHoff, D. D. (1998) · Annals of Oncology · doi:10.1023/a:1008224322396 · Cited by 137
Self-citationValoti, G., Nicoletti, M. I., Pellegrino, A., Jimeno, J. M., Hendriks, H. R., D’Incalci, M., Faircloth, G. T., & Giavazzi, R. (1998) · PubMed · Cited by 127
Self-citationEffect of adriamycin on the cell cycle traverse and kinetics of cultured human lymphoblasts.
Krishan, A., & Frei, E. (1976) · PubMed · Cited by 101
Broggini, M., Coley, H. M., Mongelli, N., Pesenti, E. A., Wyatt, M. D., Hartley, J. A., & D’Incalci, M. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.1.81 · Cited by 90
Self-citationJimeno, J. M., Faircloth, G. T., Cameron, L., Meely, K., Vega, E., Gómez, A., Sousa-Faro, J. M. F., & RINEHART, K. L. J. (1996) · Drugs of the Future · doi:10.1358/dof.1996.021.11.385487 · Cited by 87
Self-citationTakebayashi, Y., Pourquier, P., Yoshida, A., Kohlhagen, G., & Pommier, Y. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7196 · Cited by 86
Recent Progress with the DNA Repair Mutants of Chinese Hamster Ovary Cells
Thompson, L. H., Salazar, E. P., Brookman, K. W., Collins, C. C., Stewart, S. A., Busch, D. B., & Weber, C. A. (1987) · Journal of Cell Science · doi:10.1242/jcs.1984.supplement_6.6 · Cited by 83
NMR-Based Model of an Ecteinascidin 743−DNA Adduct
Moore, B. M., II, Seaman, F. C., & Hurley, L. H. (1997) · Journal of the American Chemical Society · doi:10.1021/ja9704500 · Cited by 81
Mitochondrial membrane potential measurement in rat cerebellar neurons by flow cytometry
Sureda, F. X., Escubedo, E., Gabriel, C., Comas, J., Camarasa, J., & Camins, A. (1997) · Cytometry · doi:10.1002/(sici)1097-0320(19970501)28:1 · Cited by 77
Bonsing, B. A., Corver, W. E., Gorsira, M. C. B., van Vliet, M., Oud, P. S., Cj, C., & Fleuren, G. J. (1997) · PubMed · Cited by 73
Guan, Y., Sakai, R., Rinehart, K. L., & Wang, A. H. ‐. (1993) · PubMed · Cited by 71
Bártková, J., Zemanova, M., & Bartek, J. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960611)66:6 · Cited by 62
Garcı́a-Rocha, M., García-Gravalos, M., & Ávila, J. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.176 · Cited by 52
Lee, C. S., Sun, D., Kizu, R., & Hurley, L. H. (1991) · Chemical Research in Toxicology · doi:10.1021/tx00020a013 · Cited by 45
In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743)
Ghielmini, M. E. G., Colli, E., Erba, E., Bergamaschi, D., Pampallona, S., Jimeno, J. M., Faircloth, G. T., & Sessa, C. (1998) · Annals of Oncology · doi:10.1023/a:1008430827281 · Cited by 45
Self-citationErba, E., Mascellani, E., Pifferi, A., & D’Incalci, M. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620211 · Cited by 24
Self-citation- Self-citation
Flagged first, then by citations
2 of the 28 references couldn’t be matched to a known paper.
Research works printed but not linked: 5
- Guan, 1993, Molecular and crystal structures of ecteinascidins, J. Biomol. Struct. Dyn., 10, 793
- Rayan, 1999, A phase I and pharmacokinetic trial of ecteinacidin-743 (ET-743) administered as a 72 hour continuous infusion, Proc. ASCO, 18, 188a
- Cvitkovic, 1999, Final results of phase 1 study of ecteinascidin-743 (ET-743) 24 hour (h) continuous infusion (CI) in advanced solid tumors (AST) patients (pts), Proc. ASCO, 18, 180a
- Rosing, 1999, Pharmacokinetics (PK) of Ecteinascidin-743 (ET-743) in three different phase I trials, Proc. Am. Assoc. Cancer Res., 40, 81
- Jimeno, 1999, Pharmacokinetics (PK)/pharmacodynamic (PD) relationships in patients (PT) treated with Ecteinascidin-743 (ET-743) given as 24 hours (h) continuous infusion (CI), Proc. ASCO, 18, 193a
Cited by
Sorted by citations
DNA and its associated processes as targets for cancer therapy
Hurley, L. H. (2002) · Nature reviews. Cancer · doi:10.1038/nrc749 · Cited by 1,361
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.008 · Cited by 887
Self-citationThe odyssey of marine pharmaceuticals: a current pipeline perspective
Mayer, A. M. S., Glaser, K. B., Cuevas, C., Jacobs, R. S., Kem, W. R., Little, R. D., McIntosh, J. M., Newman, D. J., Potts, B. C. M., & Shuster, D. E. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.02.005 · Cited by 669
Natural products in anticancer therapy
Ab, D. R. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00063-7 · Cited by 618
Marine Natural Products: A Source of Novel Anticancer Drugs
Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555
“Moreover, ET-743, a tetrahydroisoquinilone alkaloid isolated from tunicate Ecteinascidia turbinata entered phase I clinical trials [62], since it exerts anti-proliferative effects by selective alkylation of guanine residues in the DNA minor groove [63], whereas dolastatin 10, a member of a peptide family isolated from…”
Background
Metadata
- Authors
- Erba, E., Bergamaschi, D., Bassano, L., Damia, G., Ronzoni, S., Faircloth, G. T., & D'Incalci, M.
- Affiliations
- Mario Negri Institute for Pharmacological Research (IT)
- Rayonix (United States) (US)
- Corresponding author
- Erba, E
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2001-01
- Volume
- 37
- Issue
- 1
- Pages
- 97-105
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W2153737617
- Cited by
- 262
- References
- 28
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 7 · 2023: 7 · 2022: 8 · 2021: 7 · 2020: 6 · 2019: 6 · 2018: 6 · 2017: 8 · 2016: 10 · 2015: 21 · 2014: 19 · 2013: 9 · 2012: 4
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research Institute
- Associazione Italiana per la Ricerca sul Cancro
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Isoquinoline Alkaloid Synthesis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- trabectedin, Ecteinascidia turbinata, cell cycle arrest, p53, nucleotide excision repair, ERCC1, DNA damage, DNA-protein crosslinks, ovarian cancer cell lines, drug resistance
- MeSH terms
- Trabectedin, Cell Cycle, Cell Division, Colonic Neoplasms, Dioxoles, DNA Damage, DNA, Neoplasm, Drug Screening Assays, Antitumor, Humans, Isoquinolines, Tumor Cells, Cultured, Tumor Suppressor Protein p53, Cyclins, Antineoplastic Agents, Alkylating, Tetrahydroisoquinolines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
